Ro 3306

Product Description

Ro 3306 is an ATP-competitive cyclin-dependent kinase 1 (cdk1) inhibitor (K_i values range from 35 to 240 nM depending on cdk1 binding partner). Also reported to inhibit other cdks (K_i values are 0.89-1.32, 0.03 and >2 μM for cdk2, cdk3 and cdk4, respectively). Induces G2/M phase cell cycle arrest and apoptosis. Downregulates the expression of antiapoptotic proteins such as Bcl-2 and survivin and enhances downstream p53 signaling in acute myeloid leukemia (AML). RO 3306 also improves homology-directed repair (HDR) -mediated gene editing in hematopoietic stem and progenitor cells.

Solubility

Preparing Stock Solutions for Ro 3306

The following data is based on the product molecular weight 351.45

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	14.23 mL	71.13 mL	142.27 mL
1 mM	2.85 mL	14.23 mL	28.45 mL
2 mM	1.42 mL	7.11 mL	14.23 mL
10 mM	0.28 mL	1.42 mL	2.85 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Azhagiri Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy. Stem Cell Res.Ther. 2021 PMID: 34503562
• Jorda How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases? J.Med.Chem. 2018 PMID: 30234987
• Vassilev Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc.Natl.Acad.Sci. 2006 PMID: 16818887
• Yu CDK1 regulates mediator of DNA damage checkpoint 1 during mitotic DNA damage. Cancer Res. 2012 PMID: 22962268
• Kojima The CDK1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009 PMID: 19385969